Strategic Saudi partnership with Rawafed Health International Company targets one of the region's largest diabetes and injectable-therapy markets, supported by leading healthcare infrastructure, pharmacy access in the region
Toronto, Ontario--(Newsfile Corp. - June 26, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce that it has signed a non-binding letter of intent ("LOI") dated June 16, 2026 with Rawafed Health International Company ("Rawafed"), a leading healthcare distribution company with broad reach across pharmacy networks and healthcare infrastructure in the region. The LOI provides a pathway to entering into an exclusive distribution of TempraMed products in the Kingdom of Saudi Arabia (the "Proposed Distribution Agreement").
The LOI sets out the principal terms under which the parties intend to negotiate and enter into the Proposed Distribution Agreement, which provides for a 5-year distribution arrangement within Saudi Arabia, with exclusivity requiring minimum purchase orders from Rawafed of approximately US$3.1 million over the 5-year period. The LOI contemplates the Proposed Distribution Agreement to include performance review mechanisms, along with Rawafed providing regulatory and market-development support; however, there is no guarantee the Company and Rawafed will enter into the Proposed Distribution Agreement on the terms contemplated by the LOI or at all.
The Proposed Distribution Agreement initially includes VIVI Cap™, with additional TempraMed products potentially added by mutual agreement, including future product formats and smart solutions. Under the LOI, exclusivity would become effective following successful regulatory approval by the Saudi Food and Drug Authority ("SFDA") and placement of the first commercial order of at least US$170,000. Rawafed plans to commence the process for obtaining regulatory approval for VIVI Cap ™ upon execution of the Proposed Distribution Agreement. Given prior approval of VIVI Cap™ by the United States Food and Drug Administration, the Company expects to receive SFDA approval in due course.
Rafawed's marketing plan positions VIVI Cap Smart™ and related TempraMed products as solutions for medication protection, insulin safety, adherence support, and digital-health integration in Saudi Arabia's diabetes and injectable-medication market.
"Saudi Arabia is one of the most strategically important markets for TempraMed in the Middle East," said Ron Nagar, CEO of TempraMed. "The combination of high temperatures, a large diabetes population, expanding GLP-1 use, and growing demand for biologics and specialty injectables creates a clear need for reliable medication temperature protection."